Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface
New York, Feb 7, 2026, 14:55 EST — Market closed. Merck & Co., Inc. shares finished Friday up 1.8% at $121.93, extending a run that has put the stock back near recent highs, after the company announced a Health Canada approval for its ENFLONSIA RSV antibody for newborns and infants. (Newswire) With U.S. markets shut until Monday, the immediate question is simple: does that rally stick, or do traders fade a two-day burst of catalysts into the open? The Health Canada decision matters because ENFLONSIA (clesrovimab) is a preventive monoclonal antibody — a lab-made immune protein — and approvals tend